Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Liabilities and Shareholders Equity: 2014-2024

Historic Liabilities and Shareholders Equity for Viridian Therapeutics, Inc.\DE (VRDN) over the last 11 years, with Dec 2024 value amounting to $742.4 million.

  • Viridian Therapeutics, Inc.\DE's Liabilities and Shareholders Equity fell 25.23% to $577.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 3.41%. This contributed to the annual value of $742.4 million for FY2024, which is 51.38% up from last year.
  • As of FY2024, Viridian Therapeutics, Inc.\DE's Liabilities and Shareholders Equity stood at $742.4 million, which was up 51.38% from $490.4 million recorded in FY2023.
  • Viridian Therapeutics, Inc.\DE's Liabilities and Shareholders Equity's 5-year high stood at $742.4 million during FY2024, with a 5-year trough of $131.3 million in FY2020.
  • Its 3-year average for Liabilities and Shareholders Equity is $556.0 million, with a median of $490.4 million in 2023.
  • Data for Viridian Therapeutics, Inc.\DE's Liabilities and Shareholders Equity shows a peak YoY skyrocketed of 333.73% (in 2020) over the last 5 years.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Liabilities and Shareholders Equity (Yearly) stood at $131.3 million in 2020, then spiked by 55.20% to $203.7 million in 2021, then surged by 113.58% to $435.1 million in 2022, then rose by 12.72% to $490.4 million in 2023, then soared by 51.38% to $742.4 million in 2024.